• TRADE NAMES: Ambi (Johnson & Johnson); Lustra (Taro)
  • INDICATIONS: Ultraviolet induced dyschromia and discoloration resulting from the use of oral contraceptives, pregnancy, hormone replacement therapy, or skin trauma
  • CLASS: Depigmentation agent
  • HALF-LIFE: N/A
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    None known

Please login to view the rest of this drug profile.

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric